Details of the Drug Combinations

General Information of This Drug (ID: DMOQVU9)

Drug Name
Hydroxyurea   DMOQVU9
Synonyms
Biosupressin; Droxia; Hidrix; Hidroxicarbamida; Hydrea; Hydreia; Hydroxicarbamidum; Hydroxyaminomethanamide; Hydroxycarbamid; Hydroxycarbamide; Hydroxycarbamidum; Hydroxycarbamine; Hydroxyharnstoff; Hydroxylurea; Hydura; Hydurea; Idrossicarbamide; Litaler; Litalir; Mylocel; NHY; Oncocarbide; Oxyurea; Siklos; Carbamide oxide; Carbamohydroxamic acid; Carbamohydroximic acid; Carbamohydroxyamic acid; Carbamoyl oxime; Carbamyl hydroxamate; Carrbamoyl Oxime; Hydroxyharnstoff [German]; Idrossicarbamide [DCIT]; H 8627; SK 22591; SQ 1089; DRG-0253; Droxia (TM); Droxia (TN); HYDREA (TN); HYDROXY-UREA; Hidroxicarbamida [INN-Spanish]; Hydrea (TM); Hydroxycarbamidum [INN-Latin]; Hydroxyurea (D4); Hydroxyurea (USP); Hydroxyurea [USAN:BAN]; Hydroxyurea(d4); N-Carbamoylhydroxylamine; N-HYDROXY UREA; N-Hydroxymocovina; N-Hydroxymocovina [Czech]; N-Hydroxyurea; Onco-carbide; SQ-1089; Tetratogen: inhibits ribonucleoside diphosphate reductase; Hydroxycarbamide (JAN/INN); N-(Aminocarbonyl) Hydroxyamine; Hydrea, Biosupressin, Cytodrox, Hydroxyurea; S-phase/G-1 interface inhibitor; 1-HYDROXYUREA
Indication
Disease Entry ICD 11 Status REF
Chronic myelogenous leukaemia 2A20.0 Approved [1]
Desmoid tumour 2F7C Approved [2]
Fibromatosis N.A. Approved [2]
Head and neck cancer 2D42 Approved [2]
Melanoma 2C30 Approved [2]
Pulmonary hypertension BB01 Approved [2]
Sickle-cell anaemia 3A51 Approved [2]
⏷ Show the Full List of Indication(s)
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

8 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Acetazolamide + Hydroxyurea DC1ENCQ Acetazolamide Thalassemia [3]
Aspirin + Hydroxyurea DCYWQ39 Aspirin Thrombocythemia [4]
Imatinib + Hydroxyurea DCQYTC7 Imatinib Glioblastoma Multiforme [5]
Ruxolitinib + Hydroxyurea DC5L1H5 Ruxolitinib Myelofibrosis [6]
Temozolomide + Hydroxyurea DCMHPTO Temozolomide Glioma [7]
Verapamil + Hydroxyurea DCK37TP Verapamil Cancer [8]
Deferoxamine + Hydroxyurea DCKXEXF Deferoxamine Iron Overload [9]
Tadalafil + Hydroxyurea DCHT9CO Tadalafil Priapism Due to Sickle Cell Disease [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 8 DrugCom(s)

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6822).
2 Hydroxyurea FDA Label
3 ClinicalTrials.gov (NCT03715972) Cerebrovascular Reserve and White Matter Disease in Patients With Chronic Anemia
4 ClinicalTrials.gov (NCT00175838) Primary Thrombocythaemia 1 Trial
5 ClinicalTrials.gov (NCT00154375) Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma
6 ClinicalTrials.gov (NCT04217356) Study of Stem Cell Transplant vs. Non-Transplant Therapies in High-Risk Myelofibrosis
7 ClinicalTrials.gov (NCT03463733) Hydroxy-urea and Temozolomide in Patients With a Recurrent Malignant Brain Tumor (Glioblastoma)
8 ClinicalTrials.gov (NCT00706810) Combination of Hydroxyurea and Verapamil for Refractory Meningiomas
9 ClinicalTrials.gov (NCT04292314) Hydroxy Urea, Omega 3, Nigella Sativa,Honey on Oxidative Stress and Iron Chelation in Pediatric Major Thalassemia
10 ClinicalTrials.gov (NCT05142254) A Trial for Prevention of Recurrent Ischemic Priapism in Men With Sickle Cell Disease: A Pilot Study